 WES MOORE, Governor  Ch. 611  
 
– 1 – Chapter 611  
(House Bill 424 ) 
 
AN ACT concerning  
 
Prescription Drug Affordability Board – Authority for Upper Payment Limits  
and Stakeholder Council Membership  
(Lowering Prescription  Drug Costs for All Marylanders Now Act)  
 
FOR the purpose of altering the membership of the Prescription Drug Affordability 
Stakeholder Council;  requiring the Prescription Drug Affordability Board, under 
certain circumstances, to establish a process for setting upper payment limits for all 
purchases and payor reimbursements of prescription drug products in the State that 
the Board determines have led or will lead to affordability challenges; authorizing 
the Board to reconsider an upper payment limit for a drug that becomes a current 
shortage; altering requirements related to the setting of upper payment limits by the 
Board; requiring the Board to c onfer with the Maryland Medical Assistance Program 
before establishing an upper payment limit that applies to the Program;  prohibiting 
the Board from taking certain actions related to upper payment limits; and generally 
relating to the Prescription Drug Af fordability Board.  
 
BY repealing and reenacting, with amendments,  
 Article – Health – General  
Section 21 –2C–01, 21–2C–04, 21–2C–13, and 21 –2C–14 
 Annotated Code of Maryland  
 (2023 Replacement Volume and 2024 Supplement)  
 
BY repealing and reenacting, without amendments,  
 Article – Health – General  
Section 21–2C–09(c) and  21–2C–11(a)  
 Annotated Code of Maryland  
 (2023 Replacement Volume and 2024 Supplement)  
 
BY adding to  
 Article – Health – General  
 Section 21 –2C–09(d) and (e) and 21 –2C–16 
 Annotated Code of Maryland  
 (2023 Replacement Volume and 2024 Supplement)  
 
BY repealing  
 Article – Health – General  
Section 21 –2C–11(d) and 21 –2C–16 
 Annotated Code of Maryland  
 (2023 Replacement Volume and 2024 Supplement)  
 
BY adding to  
Ch. 611  2025 LAWS OF MARYLAND   
 
– 2 –  Article – Health – General  
Section 21 –2C–16 
 Annotated Code of Maryland  
 (2023 Replacement Volume and 2024 Supplement)  
 
 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 
That the Laws of Maryland read as follows:  
 
Article – Health – General  
 
21–2C–01. 
 
 (a) In this subtitle the following words have the meanings indicated.  
 
 (b) “Biologic” means a drug that is produced or distributed in accordance with a 
biologics license application approved under 42 C.F.R. § 447.502.  
 
 (c) “Biosimilar” means a drug that is produced or distributed in accordance with 
a biologics license application approved under 42 U.S.C. § 262(k)(3).  
 
 (d) “Board” means the Prescription Drug Affordability Board.  
 
 (e) (1) “Brand name drug” means a drug that is produced or distributed in 
accordance wi th an original new drug application approved under 21 U.S.C. § 355(c).  
 
  (2) “Brand name drug” does not include an authorized generic as defined 
by 42 C.F.R. § 447.502.  
 
 (F) “CURRENT SHORTAGE ” MEANS A DRUG : 
 
  (1) LISTED AS CURRENT ON THE FEDERAL FOOD AND DRUG 
ADMINISTRATION ’S DRUG SHORTAGE DATABASE ; OR 
 
  (2) OTHERWISE DETERMINED BY THE BOARD TO BE IN SHORT 
SUPPLY IN THE STATE . 
 
 [(f)] (G) “Generic drug” means:  
 
  (1) A retail drug that is marketed or distributed in accordance with an 
abbreviated new d rug application, approved under 21 U.S.C. § 355(j);  
 
  (2) An authorized generic as defined by 42 C.F.R. § 447.502; or  
 
  (3) A drug that entered the market before 1962 that was not originally 
marketed under a new drug application.  
 
 WES MOORE, Governor  Ch. 611  
 
– 3 –  [(g)] (H) “Manufacture r” means an entity that:  
 
  (1) (i) Engages in the manufacture of a prescription drug product; or  
 
   (ii) Enters into a lease with another manufacturer to market and 
distribute a prescription drug product under the entity’s own name; and  
 
  (2) Sets or changes the wholesale acquisition cost of the prescription drug 
product it manufactures or markets.  
 
 [(h)] (I) “Prescription drug product” means a brand name drug, a generic drug, 
a biologic, or a biosimilar.  
 
 [(i)] (J) “Stakeholder Council” means the Pr escription Drug Affordability 
Stakeholder Council.  
 
21–2C–04. 
 
 (a) There is a Prescription Drug Affordability Stakeholder Council.  
 
 (b) The purpose of the Stakeholder Council is to provide stakeholder input to assist 
the Board in making decisions as required under this subtitle.  
 
 (c) (1) The Stakeholder Council consists of [26] members appointed in 
accordance with this subsection.  
 
  (2) The Speaker of the House of Delegates shall appoint:  
 
   (i) One representative of generic drug corporations;  
 
   (ii) One representative of nonprofit insurance carriers;  
 
   (iii) One representative of a statewide health care advocacy coalition;  
 
   (iv) One representative of a statewide advocacy organization for 
seniors;  
 
   (v) One representative of a statewide org anization for diverse 
communities;  
 
   (vi) One representative of a labor union;  
 
   (vii) ONE REPRESENTATIVE OF  THE RARE DISEASE COM MUNITY ; 
 
   (VIII) One health services researcher specializing in prescription drugs; 
and 
Ch. 611  2025 LAWS OF MARYLAND   
 
– 4 –  
   [(viii)] (IX) One public member at the discretion of the Speaker of the 
House of Delegates.  
 
  (3) The President of the Senate shall appoint:  
 
   (i) One representative of brand name drug corporations;  
 
   (ii) One representative of physicians;  
 
   (iii) One representative of nurses;  
 
   (iv) One representative of hospitals;  
 
   (v) One representative of dentists;  
 
   (vi) ONE REPRESENTATIVE OF  ONCOLOGISTS ; 
 
   (VII) One representative of managed care organizations;  
 
   [(vii)] (VIII) One representative of the Department of Bud get and 
Management;  
 
   [(viii)] (IX) One clinical researcher; and  
 
   [(ix)] (X) One public member at the discretion of the President of the 
Senate.  
 
  (4) The Governor shall appoint:  
 
   (i) One representative of brand name drug corporations;  
 
   (ii) One representative of generic drug corporations;  
 
   (iii) One representative of biotechnology companies;  
 
   (iv) One representative of for –profit health insurance carriers;  
 
   (v) One representative of employers;  
 
   (vi) One representative of pharmacy benefits managers;  
 
   (vii) One representative of pharmacists;  
 
   (viii)  One pharmacologist; [and] 
 WES MOORE, Governor  Ch. 611  
 
– 5 –  
   (ix) ONE REPRESENTATIVE OF  A PATIENT ADVOCACY 
ORGANIZATION ; AND  
 
   (X) One public member at the discretion of the Governor.  
 
  (5) Collectively, the members of the Stakeholder Council shall have 
knowledge of the following:  
 
   (i) The pharmaceutical business model;  
 
   (ii) Supply chain business models;  
 
   (iii) The practice of medicine or clinical training;  
 
   (iv) Consumer or patient perspectives;  
 
   (v) Health care costs trends and drivers;  
 
   (vi) Clinical and health services research; or  
 
   (vii) The State’s health care marketplace.  
 
  (6) To the extent practicable and consistent with federal and State law, the 
membership of the Stakeholder Council shall reflect the racial, ethnic, and gender diversity 
of the State.  
 
  (7) From among the membership of the Stakeholder Council, the Board 
chair shall appoint two members to be cochairs of the Stakeholder Council.  
 
 (d) (1) The term of a member is  3 years.  
 
  (2) The initial members of the Stakeholder Council shall serve staggered 
terms as required by the terms provided for members on October 1, 2019.  
 
 (e) A member of the Stakeholder Council:  
 
  (1) May not receive compensation as a member of the Stakeholder Council; 
but 
 
  (2) Is entitled to reimbursement for expenses under the Standard State 
Travel Regulations, as provided in the State budget.  
 
21–2C–09.  
 
Ch. 611  2025 LAWS OF MARYLAND   
 
– 6 –  (c) On or before December 31, 2020, and each December 31 thereafter, the Board 
shall submi t to the Senate Finance Committee and the House Health and Government 
Operations Committee, in accordance with § 2 –1257 of the State Government Article, a 
report that includes:  
 
  (1) Price trends for prescription drug products;  
 
  (2) The number of prescription drug products that were subject to Board 
review and the results of the review; and  
 
  (3) Any recommendations the Board may have on further legislation needed 
to make prescription drug products more affordable in the State.  
 
 (D) IF THE BOARD SETS A NEW UPPER PAY MENT LIMIT , TO THE EXTENT 
PRACTICABLE , THE BOARD SHALL INCLUDE I N THE FIRST REPORT T HAT IS 
REQUIRED UNDER SUBSE CTION (C) OF THIS SECTION AFTE R THE UPPER PAYMENT 
LIMIT HAS BEEN IN EF FECT FOR 1 YEAR INFORMATION ON THE EFFECTS OF THE 
UPPER  PAYMENT LIMIT , BASED ON AVAILABLE T IMELY DATA , FOR THE FOLLOWING : 
 
  (1) PATIENT OUT –OF–POCKET COSTS INCLUDI NG WHETHER THE 
UPPER PAYMENT LIMIT WAS ASSOCIATED WITH INCREASES OR DECREAS ES IN WHAT 
PATIENTS PAY FOR PRE SCRIPTION DRUG PRODU CTS; 
 
  (2) PATIENT H EALTH INSURANCE PREM IUMS , INCLUDING WHETHER 
THE UPPER PAYMENT LI MIT IS ASSOCIATED WI TH INCREASES OR DECR EASES IN 
HEALTH INSURANCE COS TS FOR PATIENTS ; 
 
  (3) PHARMACIES OPERATING IN THE STATE , INCLUDING THE IMPACT  
ON REIMBURSEMENT RAT ES AND FINANCIAL VIA BILITY OF RETAIL AND 
INDEPENDENT PHARMACI ES; 
 
  (4) PATIENT HEALTH INSURA NCE FORMULARIES , INCLUDING 
WHETHER THE PRESCRIP TION DRUG PRODUCT SU BJECT TO THE UPPER P AYMENT 
LIMIT REMAINED ON FO RMULARIES ; 
 
  (5) PROVIDER –ADMINISTERED MEDICAT IONS SUBJECT TO THE 
UPPER  PAYMENT LIMIT , INCLUDING WHETHER PR OVIDERS WERE ABLE TO  ACQUIRE 
THE PRESCRIPTION DRU G PRODUCT SUBJECT TO  THE UPPER PAYMENT LI MIT AT A 
RATE TO ACCOUNT FOR ACQUISITION COSTS AN D WHETHER THERE WAS AN IMPACT 
ON PROVIDER REIMBURS EMENT ; 
 
  (6) PATIENT ACCESS TO  THE PRESCRIPTION DRU G PRODUCT 
SUBJECT TO THE UPPER  PAYMENT LIMIT , WHICH MAY INCLUDE : 
 
 WES MOORE, Governor  Ch. 611  
 
– 7 –    (I) WHETHER PRESCRIPTION DRUG PRODUCT SHORTAG ES OR 
OTHER SUPPLY DISRUPT IONS OCCURRED AFTER THE UPPER PAYMENT LI MIT TOOK 
EFFECT ; 
 
   (II) WHETHER FORMULARY PLA CEMENT O R PLAN DESIGN 
CHANGES MADE THE PRE SCRIPTION DRUG PRODU CT SUBJECT TO THE UP PER LIMIT 
MORE DIFFICULT FOR P ATIENTS TO ACCESS , INCLUDING IF INSURAN CE PLANS 
PREFERRED A PRESCRIP TION DRUG PRODUCT WI THOUT AN UPPER PAYME NT LIMIT 
OVER A PRESCRIPTION DRUG PRODUCT SU BJECT TO AN UPPER PA YMENT LIMIT ; 
 
   (III) WHETHER THE DISTRIBUT ION AND DELIVERY OF SPECIALTY 
OR RARE DISEASE MEDI CATIONS FROM OUT –OF–STATE PHARMACIES TO PROVIDERS , 
PHARMACIES , OR PATIENTS WAS IMPA CTED ; 
 
   (IV) WHETHER PATIENTS IN C OMMUNITIES OF COLOR , PATIENTS 
WHO ARE WOMEN , PATIENTS WITH A RARE  DISEASE , OR PATIENTS IN RURAL  AREAS 
EXPERIENCED DISPROPO RTIONATE ACCESS CHAL LENGES ; AND  
 
   (V) WHETHER COST DIFFEREN CES AS A RESULT OF T HE UPPER 
PAYMENT LIMIT AFFECT ED PATIENTS , PHARMACIES , OR PROVIDERS AND , IF THE 
COST DIFFERENCE RESU LTED IN AN INCREASE IN COSTS , WHO WAS ULTIMATELY 
RESPONSIBLE FOR BEAR ING THE INCREASED CO ST; 
 
  (7) COVERED ENTITY PROVID ERS PARTICIPATING IN  THE 340B  DRUG 
DISCOUNT PROGRAM , INCLUDING THE IMPACT  OF THE UPPER PAYMENT  LIMIT ON 
THE OP ERATIONS OF THE PROV IDERS AND THEIR CONT RACTED PHARMACIES ; AND  
 
  (8) THE BIOTECHNOLOGY IND USTRY IN THE STATE , INCLUDING THE 
IMPACT ON PHARMACEUT ICAL RESEARCH AND DE VELOPMENT , INVESTMENT , AND 
JOB GROWTH . 
 
 (E) (1) THE BOARD MAY REQUEST INF ORMATION NECESSARY TO 
COMPLETE THE REPORT REQUIRED UNDER SUBSE CTIONS (C) AND (D) OF THIS 
SECTION FROM AN AFFE CTED ENTITY . 
 
  (2) THE ENTITY FROM WHICH  INFORMATION WAS REQU ESTED UNDER 
PARAGRAPH (1) OF THIS SUBSECTION S HALL MAKE A GOOD FAI TH EFFORT TO 
PROVIDE THE REQ UESTED INFORMATION .  
 
21–2C–11. 
 
 (a) In this section, “Fund” means the Prescription Drug Affordability Fund.  
 
Ch. 611  2025 LAWS OF MARYLAND   
 
– 8 –  [(d) (1) The Board shall be established using special or general funds, which 
shall be repaid to the State with the funds from the Fund.  
 
  (2) If the Board receives funding from the Maryland Health Care 
Commission under paragraph (1) of this subsection, the Board shall repay the funds to the 
Commission from the Fund over a 3 –year period beginning June 1, 2021. ] 
 
21–2C–13. 
 
 (a) If, under § 21 –2C–07 of this subtitle, the Board finds that it is in the best 
interest of the State to establish a process for setting upper payment limits for prescription 
drug products that it determines have led or will lead to an affordability challenge, the 
Board, in c onjunction with the Stakeholder Council, shall draft a plan of action for 
implementing the process [that includes the criteria the Board shall use to set upper 
payment limits ] IN ACCORDANCE WITH T HE REQUIREMENTS OF T HIS SECTION . 
 
 (b) The criteria for sett ing upper payment limits shall include consideration of:  
 
  (1) The cost of administering the prescription drug product;  
 
  (2) The cost of delivering the prescription drug product to consumers; [and] 
 
  (3) THE EFFECT THE UPPER PAYMENT LIMIT WILL H AVE ON 
PROVIDERS OF 340B  DRUGS ; 
 
  (4) FOR AN UPPER PAYMENT LIMIT ON A DRUG THAT  IS DESIGNATED 
AS A DRUG FOR A RARE  DISEASE OR CONDITION , THE IMPACT OF THE UP PER 
PAYMENT LIMIT ON PAT IENTS WITH RARE DISE ASES ; AND 
 
  [(3)] (4) (5) Other relevant administrative costs related to the prescription 
drug product.  
 
 [(c) The process for setting upper payment limits shall:  
 
  (1) Prohibit the application of an upper payment limit for a prescription 
drug product that is on the federal Food and Drug Administration prescri ption drug 
shortage list; and  
 
  (2) Require the Board to:  
 
   (i) Monitor the availability of any prescription drug product for 
which it sets an upper payment limit; and  
 
   (ii) If there becomes a shortage of the prescription drug product in 
the State, r econsider or suspend the upper payment limit. ] 
 WES MOORE, Governor  Ch. 611  
 
– 9 –  
 (C) (1) IF THE BOARD PREVIOUSLY SET AN UPPER PAYMENT LIM IT FOR A 
DRUG THAT BECOMES A CURRENT SHORTAGE , THE BOARD MAY RECONSIDER THE 
PREVIOUSLY SET UPPER  PAYMENT LIMIT . 
 
  (2) THE BOARD MAY NOT : 
 
   (I) ESTAB LISH  APPLY  A NEW UPPER PAYMENT LIMIT FOR  TO A 
DRUG IN  A CURRENT SHORTAGE ;  
 
   (II) ENFORCE AN UPPER PAYM ENT LIMIT AGAINST PR OVIDER 
OR PHARMACY REIMBURS EMENT REQUIREMENTS F OR MEDICARE PART C OR PART 
D PLANS ; OR 
 
   (III) COUNT A PHARMACY DISP ENSING FEE TOWARD OR 
SUBJECT A PHARMACY D ISPENSING FEE TO AN UPPER PAYMENT LIMIT . 
 
 (d) (1) If a plan of action is drafted under subsection (a) of this section, the 
Board shall submit the plan of action to the Legislative Policy Committee of the General 
Assembly, in accordance with § 2 –1257 of the State Government Article, for its approval.  
 
  (2) The Legislative Policy Committee shall have 45 days to approve the 
plan of action.  
 
  (3) If the Legislative Policy Committee does not approve the plan of action, 
the Board shall submit the plan to the Governor and the Attorney General for approval.  
 
  (4) The Governor and the Attorney General shall have 45 days to approve 
the plan of action.  
 
  (5) The Board may not set upper payment limits unless the plan is 
approved, in ac cordance with this subsection, by:  
 
   (i) The Legislative Policy Committee; or  
 
   (ii) 1. The Governor; and  
 
    2. The Attorney General.  
 
21–2C–14. 
 
 [(a) If a plan of action is approved under § 21 –2C–13(d) of this subtitle ] IN 
ACCORDANCE WITH THE PLAN OF ACTION APPROVED B Y THE LEGISLATIVE POLICY 
COMMITTEE ON OCTOBER 22, 2024 , the Board may set upper payment limits  THROUGH 
REGULATIONS  for prescription drug products that are:  
Ch. 611  2025 LAWS OF MARYLAND   
 
– 10 –  
  (1) Purchased or paid for by a unit of State or local government or an 
organi zation on behalf of a unit of State or local government, including:  
 
   (i) State or county correctional facilities;  
 
   (ii) State hospitals; and  
 
   (iii) Health clinics at State institutions of higher education;  
 
  (2) Paid for through a health benefit plan on behalf of a unit of State or 
local government, including a county, bicounty, or municipal employee health benefit plan; 
or 
 
  (3) Purchased for or paid for by the Maryland State Medical Assistance 
Program.  
 
 [(b) The upper payment limits set under subsection (a) of this section shall:  
 
  (1) Be for prescription drug products that have led or will lead to an 
affordability challenge; and  
 
  (2) Be set in accordance with the criteria established in regulations 
adopted by the Board.  
 
 (c) (1) The Board shall:  
 
   (i) Monitor the availability of any prescription drug product for 
which it sets an upper payment limit; and  
 
   (ii) If there becomes a shortage of the prescription drug product in 
the State, reconsider whether the upper payment limit should be suspended or altered.  
 
  (2) An upper payment limit set under subsection (a) of this section may not 
be applied to a prescription drug product while the prescription drug product is on the 
federal Food and Drug Administration prescription drug shortage lis t.] 
 
[21–2C–16. 
 
 On or before December 1, 2026, the Board, in consultation with the Stakeholder 
Council, shall report to the Senate Finance Committee and the House Health and 
Government Operations Committee, in accordance with § 2 –1257 of the State Government 
Article, on:  
 
 WES MOORE, Governor  Ch. 611  
 
– 11 –   (1) The legality, obstacles, and benefits of setting upper payment limits on 
all purchases and payor reimbursements of prescription drug products in the State; and  
 
  (2) Recommendations regarding whether the General Assembly sho uld 
pass legislation to expand the authority of the Board to set upper payment limits to all 
purchases and payor reimbursements of prescription drug products in the State. ] 
 
21–2C–16. 
 
 (A) (1) THE BOARD , IN CONSULTATION WITH  THE STAKEHOLDER 
COUNCIL , SHALL  DETERMINE WHETHER , IN ADDITION TO SETTI NG UPPER PAYMENT 
LIMITS IN ACCORDANCE  WITH § 21–2C–14 OF THIS SUBTITLE , IT IS IN THE BEST 
INTEREST OF THE STATE FOR THE BOARD TO ESTABLISH A PROCESS FOR SETTING 
UPPER PAYMENT LIMITS  FOR ALL  PURCHASES AND PAYOR REIMBU RSEMENTS OF 
PRESCRIPTION DRUG PR ODUCTS IN THE STATE THAT THE BOARD DETERMINES 
HAVE LED OR WILL LEA D TO AN AFFORDABILIT Y CHALLENGE . 
 
  (2) WHEN MAKING A DETERMI NATION UNDER PARAGRA PH (1) OF 
THIS SUBSECTION , THE BOARD SHALL CONSIDER , IF APPLICABLE : 
 
   (I) CONTRACT AND BUDGET D ATA PROVIDED TO THE BOARD 
THAT DEMONSTRATES SA VINGS TO THE STATE OR LOCAL GOVERN MENTS AS A 
RESULT OF UPPER PAYM ENT LIMITS SET IN AC CORDANCE WITH § 21–2C–14 OF THIS 
SUBTITLE ; 
 
   (II) SUCCESS OF SETTING UP PER PAYMENT LIMITS I N OTHER 
STATES; AND 
 
   (III) EXPECTED SAVINGS FROM  MEDICARE MAXIMUM FAIR 
PRICES SET BY THE CENTERS FOR MEDICARE AND MEDICAID SERVICES . 
 
 (B) (1) IF THE BOARD MAKES AN AFFIRM ATIVE DETERMINATION UNDER 
SUBSECTION (A) OF THIS SECTION , THE BOARD , IN CONSULTATION WITH  THE  
STAKEHOLDER COUNCIL , SHALL ESTABLISH A PR OCESS FOR SETTING UP PER 
PAYMENT LIMITS FOR ALL  PURCHASES AND PAYOR REIMBURSEMENTS OF 
PRESCRIPTION DRUG PR ODUCTS IN THE STATE THAT THE BOARD DETERMINES 
HAVE LED OR WILL LEA D TO AN AFFORDABILIT Y CHALLENGE . 
 
  (2) THE PROCESS ESTABLISHED UNDER PARAGRAPH (1) OF THIS 
SUBSECTION SHALL : 
 
   (I) TO THE EXTENT APPROPR IATE , USE THE PLAN OF ACTI ON 
APPROVED UNDER § 21–2C–13(D) OF THIS SUBTITLE ; AND 
Ch. 611  2025 LAWS OF MARYLAND   
 
– 12 –  
   (II) OTHERWISE COMPLY WITH  THE REQUIREMENTS FOR  
SETTING UPPER PAYMEN T LIMITS  ESTABLISHED UNDER TH IS SUBTITLE . 
 
  (3) BEFORE ESTABLISHING A N UPPER PAYMENT LIMI T THAT APPLIES 
TO THE MARYLAND MEDICAL ASSISTANCE PROGRAM , THE BOARD SHALL CONFER 
WITH THE MARYLAND MEDICAL ASSISTANCE PROGRAM TO APPROVE TH E 
APPLICATION OF THE U PPER PAYMENT  LIMIT BY ASSESSING W HETHER THE 
PROPOSED UPPER PAYME NT LIMIT WILL : 
 
   (I) CONFLICT WITH THE MEDICAID DRUG REBATES 
PROGRAM , THE COVERED OUTPATIENT DRUG RULE (CMS–2345–FC),  OR ANY 
OTHER FEDERAL REQUIR EMENTS AS APPLICABLE ; AND 
 
   (II) REQUIRE ADDITIONAL FU NDING TO BE ALLOCATED  TO THE 
MARYLAND MEDICAL ASSISTANCE PROGRAM BUDGET .  
 
 SECTION 2. AND BE IT FURTHER ENACTED, That the Laws of Maryland read 
as follows:  
 
Article – Health – General  
 
21–2C–16. 
 
 (C) (1) IF SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION , IF THE 
BOARD ESTABLISHES A P ROCESS UNDER SUBSECT ION (B) OF THIS SECTION , THE 
BOARD SHALL SET UPPER  PAYMENT LIMITS FOR ALL  PURCHASES AND PAYOR 
REIMBURSEMENTS OF PR ESCRIPTION DRUG PROD UCTS IN THE STATE IN 
ACCORDANCE WITH THE PROCESS .  
 
  (2) THIS SUBSECTION DO ES NOT APPLY WITH RE SPECT TO : 
 
   (I) PAYOR REIMBURSEMENTS UNDER MEDICARE PART C AND 
D PLANS ; 
 
   (II) PURCHASES UNDER THE F EDERAL 340B  DRUG PRICING 
PROGRAM ; AND 
 
   (III) PURCHASES AND PAYOR R EIMBURSEMENTS UNDER  BY 
FEDERAL AGENCIES OR  FEDERAL PROGRAMS THA T ARE  THE STATE IS  PREEMPTED  
FROM REGULATING  BY FEDERAL LAW  INCLUDING : 
 
    1. THE DEPARTMENT OF DEFENSE ; 
 WES MOORE, Governor  Ch. 611  
 
– 13 –  
    2. THE DEPARTMENT OF VETERANS AFFAIRS ; 
 
    3. THE PUBLIC HEALTH SERVICE ; 
 
    4. THE UNITED STATES COAST GUARD ; 
 
    5. TRICARE ; 
 
    6. THE FEDERAL EMPLOYEES HEALTH BENEFIT PLAN; 
AND 
 
    7. ANY OTHER EXCLUSIVE F EDERAL PROGRAM AS 
APPLICABLE .  
 
 SECTION 3. AND BE IT FURTHER ENACTED, That:  
 
 (a) Section 2 of this Act is contingent on the Prescription Drug Affordability Board 
setting upper payment limits on two prescription drugs in accordance with § 21 –2C–14 of 
the Health – General Article, as enacted by Section 1 of this Act, and each upper payme nt 
limit being in effect for 1 year.  
 
 (b) Within 5 days after the conditions described in subsection (a) of this section 
are met, the Prescription Drug Affordability Board shall notify the Department of 
Legislative Services.  
 
 (c) If notice is received by  the Department of Legislative Services in accordance 
with subsection (b) of this section on or before September 31  September 30 , 2030, Section 2 
of this Act shall take effect on the date the notice is received by the Department of 
Legislative Services.  
 
 (d) If notice is not received by the Department of Legislative Services on or before 
December 31  September 30 , 2030, Section 2 of this Act, with no further action required by 
the General Assembly, shall be null and void.  
 
 SECTION 4. AND BE IT FURTHER ENAC TED, That, subject to Section 3 of this 
Act, this Act shall take effect October 1, 2025.  
 
Approved by the Governor, May 20, 2025.  